White papers and Application Notes (Free Download)
Access a curated selection of technical papers offering in-depth insights into VHH research and applications. Each document is grounded in scientific rigour and developed to support discovery and innovation.
Application Note “Understanding the VHH Format”
This application note provides a scientific overview of the structural and functional properties of VHH antibodies. Written for researchers working in antibody discovery and engineering, it explains how the VHH format supports challenging targets, advanced therapeutic formats and modern biologics development.
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy
Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable.
Advantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note, which includes:
- a review of the bi-specific mechanisms of action, key targets and our clinical development pipeline
- a summary of Isogenica’s multi-specific plug-and-play platform
- exemplar data using our synthetic VHH antibodies
Optimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.
Isogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production.
Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery…